326 related articles for article (PubMed ID: 31371956)
1. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
2. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
3. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
4. Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Wu C; Zhang Y; Yang D; Zhang J; Ma J; Cheng D; Chen J; Deng L
Int J Nanomedicine; 2019; 14():75-85. PubMed ID: 30587986
[TBL] [Abstract][Full Text] [Related]
5. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
6. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
9. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
11. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
13. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X
J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
16. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
18. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy.
Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y
J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551
[TBL] [Abstract][Full Text] [Related]
19. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
[TBL] [Abstract][Full Text] [Related]
20. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]